Drug Profile
Milatuzumab - Immunomedics
Alternative Names: hCD74; hLL1; Humanised anti-CD74; IMMU-115Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Immunomedics
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Chronic lymphocytic leukaemia; Graft-versus-host disease; Haematological malignancies; Multiple myeloma; Non-Hodgkin's lymphoma; Systemic lupus erythematosus
Most Recent Events
- 01 Feb 2021 Immunomedics completes a phase Ib trial in Systemic Lupus Erythematosus in US (NCT01845740)
- 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
- 30 Sep 2020 Discontinued - Phase-I for Graft-versus-host disease (Adjunctive treatment, Combination therapy) in USA (IV)